-+ 0.00%
-+ 0.00%
-+ 0.00%
Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans
Share
Listen to the news
Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans
  • Aurinia highlighted continued commercial growth for lupus nephritis drug LUPKYNIS.
  • Six months ended June 30, 2026: total revenue USD 160.9 million; net income USD 71.8 million; operating cash flow USD 85.1 million.
  • 2026 guidance: total revenue USD 315 million to USD 325 million; net product sales USD 305 million to USD 315 million.
  • Pipeline focus included advancing aritinercept development in autoimmune disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending